UNSPSC 51371504: Doxpicomine

This classification denotes an analgesic agent with the molecular formula C12H18N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9821373UA1, chemically known as 1-(1,3-dioxan-5-yl)-N,N-dimethyl-1-pyridin-3-ylmethanamine but generally known as doxpicomine, which bears US NIH Compound Identifier 71979. European Medicines Agency schedules doxpicomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06392MIG. Most nations schedule doxpicomine under HS 29349990 and SITC 51579.

As of Q4 2014, DOXPICOMINE remains the US FDA Preferred Term for this commodity. Doxpicomine bears US NLM identifiers UMLS ID C0058730 and NCI Concept Code C65477. SMILES: CN(C)C(C1COCOC1)C2=CN=CC=C2.Cl.

UNSPSC 51371504 Doxpicomine is a Commodity code that describes pharmaceutical products state and local governments procure through health departments, cooperative purchasing alliances, and county health systems—though recent solicitations tagged to this code show minimal activity specifically for doxpicomine itself, instead capturing broader pharmaceutical procurement for naloxone, generic multi-source drugs, and OTC products. State and local issuing bodies under this code span county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon). The work involves procurement of finished pharmaceutical products for community health initiatives, emergency response supply chains, and state employee health benefits, with vendors required to manage supply-chain compliance including FDA certification, cGMP compliance, Drug Supply Chain Security Act adherence, wholesaler relationships, and insurance requirements (commercial general liability of $2,000,000 to $5,000,000, workers' compensation, and professional liability).

Recent activity appears concentrated in Florida and the upper Midwest through cooperative purchasing. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023 (note: deadline date appears inconsistent with posting date). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program outside traditional pharmacy benefit manager and group purchasing organization channels, with response due April 3, 2026. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, requiring submission through ePro in CSV format by March 26, 2026, with awards effective July 1, 2026 and a two-year initial contract term; MMCAP reserves multi-award authority based on therapeutic considerations and member-specific needs.